-+ 0.00%
-+ 0.00%
-+ 0.00%
What Gilead Sciences Doubters Missed
Share
Listen to the news

If Gilead Sciences sat on your watchlist instead of in your portfolio, this year’s move may feel like a missed call. Investors who held Gilead Sciences from the start of the year are up 40.3%, including dividends. That outcome sharpened an earlier split between bulls who focused on lenacapavir and Trodelvy serving an aging population and bears who worried about Medicare Part D pressure. If you were staring at that disagreement on 1 January, which business story deserved more weight?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

This theme extends beyond Gilead Sciences. See which of 36 healthcare AI stocks may still merit a closer look.

The Two Gilead Sciences Stories Investors Had To Weigh

Gilead Sciences shares cost US$123 at the start of the period, and investors were pulled between two sharply different but reasonable stories about what that price implied.

The bullish Narrative pointed to a Fair Value of US$141, built on lenacapavir and Trodelvy expanding into larger markets and on the assumption that revenue could grow 5.6% a year with profit margins rising from 20.8% to 32.0% by 2028.

The bearish Narrative set Fair Value at US$91. This view highlighted Medicare Part D pressure on HIV pricing and assumed slower 1.6% annual revenue growth with margins reaching 26.8% instead.

NasdaqGS:GILD Trailing 12-Month Earnings & Revenue History as at Nov 2026
NasdaqGS:GILD Trailing 12-Month Earnings & Revenue History as at Nov 2026

What The Evidence Told Investors About Gilead Sciences

The clearest new data point was Gilead Sciences lifting its 2026 revenue outlook on stronger HIV and oncology demand while booking large acquisition related charges and a lower earnings guide. Quarterly numbers showed revenue at US$8.3b and net income at US$2.4b, with net margin down from 39.3% to 29.3%. The period cut both ways for the optimistic and cautious cases.

The hinge assumption was not just growth, but the quality of that growth. For a different stock, you would test any margin expansion story directly against reported net income and net margin, not only the top line or new product headlines.

What You Are Paying For In Gilead Sciences After A 40% Run

Gilead Sciences now trades at US$168, and the current Narrative’s Fair Value sits below that level based on its own assumptions rather than any hard rule.

According to kapirey, an investor in the Simply Wall St Community, the memo leans on durable HIV cash flows, pipeline breadth and M&A, so a buyer today is effectively assuming acquisitions integrate smoothly and near term earnings dilution does not derail that story.

"Bull case: Market is underappreciating the growth potential of lenacapavir (PrEP) and oncology pipeline scale-up. Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Another Question Gilead Raises

Watching Gilead Sciences sharpen its HIV and oncology focus may steer your attention elsewhere. One step away, a different business leans on a similar mix.

This other drug maker is also pushing cancer treatments that rely on targeted antibody drug conjugates. It is trying to move some of those therapies earlier in care.

Alongside that, it is building out vaccines and other specialty medicines. Management is also working through a long list of cost savings.

The aim is to free more cash for future drugs or share count actions. If that shift really sticks, the story could look very different.

One Narrative has already put a figure on it. → Uncover the company trading 22% below one Narrative's Fair Value

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending